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Letters to the Editor
Defining Refractory Pain in Cancer
for Clinicians and Researchers
David C. Currow, B.Med., M.P.H., FRACP,1 Odette Spruyt, MBChB, Dip Obs, FRACP, FAChPM,2
and Janet Hardy, B.Sc., MBChB, M.D., FRACP3
Dear Editor:
Managing pain in people with cancer remains a challenge,
especially in those referred to as having refractory pain. But
what is refractory or intractable pain?1,2 Until there is a stan-
dard definition there is the risk that: a) clinically, new medi-
cations are continuously added, each with diminishing returns
in reducing pain, and each with an increasing likelihood of
toxicity as the only noticeable change; and b) in research, there
will be differing baselines for the operational definition of re-
fractory, making it difficult to adopt the findings into practice,
or to compare clinical trials in any systematic way.
Recognition of this heterogeneity led to the recognition of
poor prognostic factors in pain management.3–5 Factors con-
tributing to pain that proves difficult to control include the un-
derlying etiology of the pain (often reflected in the description
of the pain), incident pain, concomitant psychological distress,
younger age, and pain intensity. Clinical impression also indi-
cates that patients with a prolonged period between onset of
pain and initiating adequate therapy, previous long-term an-
algesic use for other pain, and impaired cognition (especially
because it limits use of many nonpharmacological interven-
tions) may also have pain that is more difficult to control.
Refractory pain can be defined as pain that has persisted
over time despite an adequate trial of analgesic therapies and
nonpharmacological approaches including the recognition
and response to suffering.6 This must specify not only medi-
cation selection but also dose and duration of use. Such a
definition need not set an arbitrary time between the onset of
pain and initiation of therapies nor the subsequent time before
pain is labelled ‘‘refractory.’’
A standard definition of refractory pain requires:
- a classification of the type of pain experienced using a
tool such as the Edmonton Pain classification3,4;
- consistent use of diagnostic criteria such as the LANSS7;
and
- a peer reviewed and agreed combination of evidence-
based medications with accepted doses and duration.
The longer a person has poorly controlled pain and the more
interventions that are trialled to control the pain, the greater the
likelihood that the patient will be exposed to therapies without
an established level I or II evidence base. Such therapies cur-
rently include combination opioid therapy, opioid rotation, the
use ofmany co-analgesics, and complimentary therapies. As the
benefit of so many of these interventions is unproven, they
should ideally only be made available therapeutically in the
setting of adequately designed and powered clinical trials. If a
suitable trial is not available, there should be rigorous pro-
spective evaluation for net clinical benefit including toxicity
using standardized tools and data collection systems. This
would require considerable reorganization of clinical practice
and is an approach thatwould be applicable inmany conditions
without adequate evidence base.
Pain uncontrolled by a rigorous trial of a combination of
evidence-based therapies should be the starting point for a
definition of refractory. This should not include therapies
with level III or lower evidence.8
Clinicians in hospice and palliative care often criticize their
oncological colleagues for offering off-label third-, fourth-, or
fifth-line anticancer therapy with rapidly diminishing benefit
and a relative shift in the therapeutic ratio towards toxicity.
Oncologists often defend this action on the grounds that ‘‘there
is nothing else to offer.’’ In hospice and palliative care, we are
at risk of similar behavior with the treatment of refractory pain
unless there is an agreed taxonomy for the diagnosis which
clinicians and researchers can operationalize uniformly.
The multidimensional nature of pain, the absence of ob-
jective measures of response, and the palpable distress of se-
vere pain all contribute particular challenges to clinicians who
are intent on relieving suffering. Working toward better
consistency of terminology is important for all symptoms
when terms such as ‘‘refractory’’ are used.
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